-+ 0.00%
-+ 0.00%
-+ 0.00%

Simcere Zaiming licenses SIM0660 to Roche in deal worth up to $ 1.53 billion

PUBT·09/02/2026 08:01:51
Listen to the news
Simcere Zaiming licenses SIM0660 to Roche in deal worth up to $ 1.53 billion
  • Simcere Zaiming, a Simcere Pharmaceutical Group unit, granted Roche exclusive global rights to develop, manufacture, market tri-specific antibody SIM0660.
  • Deal terms include USD 75 million upfront, up to USD 1.53 billion total payments, tiered royalties reaching double-digit percentages.
  • SIM0660 targets CD79a, CD19, CD3 for B-cell-mediated diseases; positioned as an option for patients previously treated with CD20 or CD19 therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609020400PR_NEWS_EURO_ND__NL38066) on September 02, 2026, and is solely responsible for the information contained therein.